

"This application is a continuation of application Serial No. 10/008,516, filed November 8, 2001, now US Patent No. 6,649,607."

IN THE CLAIMS

Please amend claims 1-5 and 28-32 as follows:

1. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier.
2. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 85% or more by weight of the total weight of tofisopam.
3. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 90% or more by weight of the total weight of tofisopam.

4. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 95% or more by weight of the total weight of tofisopam.
5. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.
28. (Currently amended) The pharmaceutical composition according to claim 1, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, transdermal delivery or oral administration.
29. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 10 mg to 1200 mg
30. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-

tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

31. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.

32. (Currently amended) A method of administering a pharmaceutical composition according to claim 1, comprising preparing the pharmaceutical composition comprising of S-tofisopam, pro-drug or pharmaceutically acceptable salt thereof and administering the pharmaceutical composition at a dose of less than 30 mg/kg.

#### **REMARKS**

Applicants request acceptance of the claims of the present application in view of the above amendments and the following remarks.

#### **OBJECTIONS**

As requested by the Examiner, the following statement has been incorporated at the beginning of the specification: "This application is a continuation of